Stronger Neo-Minophagen C™, a glycyrrhizin-containing preparation, protects liver against carbon tetrachloride-induced oxidative stress in transgenic mice expressing the hepatitis C virus polyprotein

Liver International

Volumn 27, Issue 6, 2007, Pages 845-853

  Hidaka, Isao ^a   Hino, Keisuke ^a   Korenaga, Masaaki ^a   Gondo, Toshikazu ^b   Nishina, Sohji ^a   Ando, Miye ^a   Okuda, Michiari ^a   Sakaida, Isao ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YAMAGUCHI UNIVERSITY HOSPITAL   (Japan)

Author keywords

glutamylcysteine synthetase; Cytochrome P450 2E1; Glutathione; Mitochondria

Indexed keywords

ALANINE AMINOTRANSFERASE; CARBON TETRACHLORIDE; CYSTEINE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLYCINE; GLYCYRRHIZIC ACID; MALONALDEHYDE; MESSENGER RNA; NEO MINOPHAGEN C; NEOMINOPHAGEN C; POLYPROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROTECTION; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG MECHANISM; HEPATITIS C; HEPATITIS C VIRUS; LIVER CELL; LIVER INJURY; LIVER MITOCHONDRION; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ALANINE TRANSAMINASE; ANIMALS; ANTIOXIDANTS; CARBON TETRACHLORIDE; CYSTEINE; CYTOCHROME P-450 CYP2E1; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; GLYCINE; GLYCYRRHETINIC ACID; HEPACIVIRUS; LIVER; LIVER DISEASES; MALE; MALONDIALDEHYDE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MITOCHONDRIA, LIVER; OXIDATIVE STRESS; POLYPROTEINS; RNA, MESSENGER; VIRAL PROTEINS;

EID: 34447298339     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2007.01492.x     Document Type: Article

References (38)

1. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14: 969-74.
2. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797-801.
3. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-6.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958-65.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
6. Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European concerted action on viral heaptitis (EUROHEP). J Hepatol 1997; 27: 201-5.
7. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka liver disease study group. Hepatology 1998; 27: 1394-402.
8. Finney RSH, Somers GF. The anti-inflammatory activity of glycyrrhetinic acid and derivatives. J Pharm Pharmacol 1958; 10: 613-20.
9. Nakamura T, Fujii T, Ichihara A. Enzyme leakage due to change of membrane permeability of primary cultured rat hepatocytes treated with various hepatotoxins and its prevention by glycyrrhizin. Cell Biol Toxicol 1985; 1: 285-95.
10. Shiki Y, Shirai K, Saito Y, Yoshida S, Mori Y, Wakashin M. Effect of glycyrrhizin on lysis of hepatocyte membranes induced by anti-liver cell membrane antibody. J Gastroenterol Hepatol 1992; 7: 12-6.
11. Suzuki H, Ohta Y, Takino T, Fujisawa K, Hirayama C. Effects of glycyrrhizin on biochemical tests in patients with chronic hepatitis. Asian Med J 1983; 26: 423-38.
12. Orlent H, Hansen BE, Willems M, et al. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: A randomized phase II trial. J Hepatol 2006; 45: 539-46.
13. Arase Y, Ikeda K, Murashima N, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79: 1494-500.
14. Barbaro G, Di Lorenzo G, Asti A, et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: Ultrastructural and biochemical findings. Am J Gastroenterol 1999; 94: 2198-205.
15. Valgimigli M, Valgimigli L, Trere D, et al. Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation. Free Radic Res 2002; 36: 939-48.
16. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-75.
17. Korenaga M, Wang T, Li Y, et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 2005; 280: 37481-8.
18. Jain SK, Pemberton PW, Smith A, et al. Oxidative stress in chronic hepatitis C: Not just a feature of late stage disease. J Hepatol 2002; 36: 805-11.
19. Paradis V, Mathurin P, Kollinger M, et al. In situ detection of lipid peroxidation in chronic hepatitis C: Correlation with pathological features. J Clin Pathol 1997; 50: 401-6.
20. Kitase A, Hino K, Furutani T, et al. In situ detection of oxidized n-3 polyunsaturated fatty acids in chronic hepatitis C: Correlation with hepatic steatosis. J Gastroenterol 2005; 40: 617-24.
21. Furutani T, Hino K, Okuda M, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 2006; 130: 2087-98.
22. Beard MR, Abell G, Honda M, et al. An infectious molecular clone of a Japanese genotype 1b hepatitis C virus. Hepatology 1999; 30: 316-24.
23. Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002; 122: 352-65.
24. Yagi K. A simple fluorometric assay for lipoperoxide in blood plasma. Biochem Med 1976; 15: 212-6.
25. Healy LN, Pluta LJ, Recio L. Expression and distribution of cytochrome P450 2E1 in B6C3F1 mouse liver and testes. Chem Biol Interact 1999; 121: 199-207.
26. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
27. Recknagel RO, Glende EA Jr, Dolak JA, Waller RL. Mechanisms of carbon tetrachloride toxicity. Pharmacol Ther 1989; 43: 139-54.
28. Yan N, Meister A. Amino acid sequence of rat kidney gamma-glutamylcysteine synthetase. J Biol Chem 1990; 265: 1588-93.
29. Gipp JJ, Bailey HH, Mulcahy RT. Cloning and sequencing of the cdna for the light subunit of human liver gamma-glutamylcysteine synthetase and relative mrna levels for heavy and light subunits in human normal tissues. Biochem Biophys Res Commun 1995; 206: 584-9.
30. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC goups. Lancet 1997; 349: 825-32.
31. Kato J, Kobune M, Nakamura T, et al. Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 2001; 61: 8697-702.
32. Murakami C, Hino K, Korenaga M, et al. Factors predicting progression to cirrhosis and hepatocellular carcinoma in patients with transfusion-associated hepatitis C virus infection. J Clin Gastroenterol 1999; 28: 148-52.
33. Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: Carbon tetrachloride as a toxicological model. Crit Rev Toxicol 2003; 33: 105-36.
34. Jeong HG, You HJ, Park SJ, et al. Hepatoprotective effects of 18beta-glycyrrhetinic acid on carbon tetrachloride-induced liver injury: inhibition of cytochrome P450 2E1 expression. Pharmacol Res 2002; 46: 221-7.
35. Wang L, Potter JJ, Rennie-Tankersley L, Novitskiy G, Sipes J, Mezey E. Effects of retinoic acid on the development of liver fibrosis produced by carbon tetrachloride in mice. Biochim Biophys Acta 2007; 1772: 66-71.
36. Lopez-Diazguerrero NE, Luna-Lopez A, Gutierrez-Ruiz MC, Zentella A, Konigsberg M. Susceptibility of DNA to oxidative stressors in young and aging mice. Life Sci 2005; 77: 2840-54.
37. Tomasi A, Albano E, Banni S, et al. Free-radical metabolism of carbon tetrachloride in rat liver mitochondria. A study of the mechanism of activaion. Biochem J 1987; 246: 313-7.
38. Lu SC. Regulation of hepatic glutathione synthesis: Current concepts and controversies. FASEB J 1999; 13: 1169-83.